Literature DB >> 14533979

Catalytic- and ecto-domains of membrane type 1-matrix metalloproteinase have similar inhibition profiles but distinct endopeptidase activities.

Douglas R Hurst1, Martin A Schwartz, Mohammad A Ghaffari, Yonghao Jin, Harald Tschesche, Gregg B Fields, Qing-Xiang Amy Sang.   

Abstract

Membrane type 1-matrix metalloproteinase (MT1-MMP/MMP-14) is a major collagenolytic enzyme that plays a vital role in development and morphogenesis. To elucidate further the structure-function relationship between the human MT1-MMP active site and the influence of the haemopexin domain on catalysis, substrate specificity and inhibition kinetics of the cdMT1-MMP (catalytic domain of MT1-MMP) and the ecto domain DeltaTM-MT1-MMP (transmembrane-domain-deleted MT1-MMP) were compared. For substrate 1 [Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH(2), where Mca stands for (7-methoxycoumarin-4-yl)acetyl- and Dpa for N -3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl], the activation energy E (a) was determined to be 11.2 and 12.2 kcal/mol (1 cal=4.184 J) for cdMT1-MMP and DeltaTM-MT1-MMP respectively, which is consistent with k (cat)/ K (M) values of 7.37 and 1.46x10(4) M(-1).s(-1). The k (cat)/ K (M) values for a series of similar single-stranded peptide substrates were determined and found to correlate with a slope of 0.17 for the two enzyme forms. A triple-helical peptide substrate was predicted to have a k (cat)/ K (M) of 0.87x10(4) M(-1).s(-1) for DeltaTM-MT1-MMP based on the value for cdMT1-MMP of 5.12x10(4) M(-1).s(-1); however, the actual value was determined to be 2.5-fold higher, i.e. 2.18x10(4) M(-1).s(-1). These results suggest that cdMT1-MMP is catalytically more efficient towards small peptide substrates than DeltaTM-MT1-MMP and the haemopexin domain of MT1-MMP facilitates the hydrolysis of triple-helical substrates. Diastereomeric inhibitor pairs were utilized to probe further binding similarities at the active site. Ratios of K (i) values for the inhibitor pairs were found to correlate between the enzyme forms with a slope of 1.03, suggesting that the haemopexin domain does not significantly modify the enzyme active-site structure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14533979      PMCID: PMC1223890          DOI: 10.1042/BJ20031067

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  25 in total

1.  Hydrolysis of triple-helical collagen peptide models by matrix metalloproteinases.

Authors:  J L Lauer-Fields; K A Tuzinski; K i Shimokawa; H Nagase; G B Fields
Journal:  J Biol Chem       Date:  2000-05-05       Impact factor: 5.157

2.  The recombinant catalytic domain of membrane-type matrix metalloproteinase-1 (MT1-MMP) induces activation of progelatinase A and progelatinase A complexed with TIMP-2.

Authors:  A Lichte; H Kolkenbrock; H Tschesche
Journal:  FEBS Lett       Date:  1996-11-18       Impact factor: 4.124

Review 3.  Relating matrix metalloproteinase structure to function: why the "hemopexin" domain?

Authors:  G Murphy; V Knäuper
Journal:  Matrix Biol       Date:  1997-03       Impact factor: 11.583

4.  Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases.

Authors:  M P d'Ortho; H Will; S Atkinson; G Butler; A Messent; J Gavrilovic; B Smith; R Timpl; L Zardi; G Murphy
Journal:  Eur J Biochem       Date:  1997-12-15

5.  Identification and characterization of human endometase (Matrix metalloproteinase-26) from endometrial tumor.

Authors:  H I Park; J Ni; F E Gerkema; D Liu; V E Belozerov; Q X Sang
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

6.  Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity.

Authors:  D Pei; S J Weiss
Journal:  J Biol Chem       Date:  1996-04-12       Impact factor: 5.157

7.  New thiol and sulfodiimine metalloproteinase inhibitors and their effect on human microvascular endothelial cell growth.

Authors:  Q X Sang; M C Jia; M A Schwartz; M C Jaye; H K Kleinman; M A Ghaffari; Y L Luo
Journal:  Biochem Biophys Res Commun       Date:  2000-08-11       Impact factor: 3.575

8.  Expression of human membrane type 1 matrix metalloproteinase in Pichia pastoris.

Authors:  M Roderfeld; F H Büttner; E Bartnik; H Tschesche
Journal:  Protein Expr Purif       Date:  2000-08       Impact factor: 1.650

9.  Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases.

Authors:  I Yana; S J Weiss
Journal:  Mol Biol Cell       Date:  2000-07       Impact factor: 4.138

10.  Immunological characterization of cell-surface and soluble forms of membrane type 1 matrix metalloproteinase in human breast cancer cells and in fibroblasts.

Authors:  H Li; D E Bauzon; X Xu; H Tschesche; J Cao; Q A Sang
Journal:  Mol Carcinog       Date:  1998-06       Impact factor: 4.784

View more
  19 in total

1.  Using fluorogenic peptide substrates to assay matrix metalloproteinases.

Authors:  G B Fields
Journal:  Methods Mol Biol       Date:  2001

2.  Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors.

Authors:  Janelle Lauer-Fields; Keith Brew; John K Whitehead; Shunzi Li; Robert P Hammer; Gregg B Fields
Journal:  J Am Chem Soc       Date:  2007-08-02       Impact factor: 15.419

3.  Development of a solid-phase assay for analysis of matrix metalloproteinase activity.

Authors:  Janelle L Lauer-Fields; Hideaki Nagase; Gregg B Fields
Journal:  J Biomol Tech       Date:  2004-12

4.  Development of a Förster resonance energy transfer assay for monitoring bacterial collagenase triple-helical peptidase activity.

Authors:  Michal Tokmina-Roszyk; Dorota Tokmina-Roszyk; Manishabrata Bhowmick; Gregg B Fields
Journal:  Anal Biochem       Date:  2014-03-06       Impact factor: 3.365

5.  The interface between catalytic and hemopexin domains in matrix metalloproteinase-1 conceals a collagen binding exosite.

Authors:  Laurence H Arnold; Louise E Butt; Stephen H Prior; Christopher M Read; Gregg B Fields; Andrew R Pickford
Journal:  J Biol Chem       Date:  2011-10-26       Impact factor: 5.157

6.  Collagenolytic Matrix Metalloproteinase Activities toward Peptomeric Triple-Helical Substrates.

Authors:  Maciej J Stawikowski; Roma Stawikowska; Gregg B Fields
Journal:  Biochemistry       Date:  2015-05-05       Impact factor: 3.162

Review 7.  Synthesis and biological applications of collagen-model triple-helical peptides.

Authors:  Gregg B Fields
Journal:  Org Biomol Chem       Date:  2010-01-20       Impact factor: 3.876

8.  Characterization and regulation of MT1-MMP cell surface-associated activity.

Authors:  Sonia Pahwa; Manishabrata Bhowmick; Sabrina Amar; Jian Cao; Alex Y Strongin; Rafael Fridman; Stephen J Weiss; Gregg B Fields
Journal:  Chem Biol Drug Des       Date:  2018-12-19       Impact factor: 2.817

9.  Identification of specific hemopexin-like domain residues that facilitate matrix metalloproteinase collagenolytic activity.

Authors:  Janelle L Lauer-Fields; Michael J Chalmers; Scott A Busby; Dmitriy Minond; Patrick R Griffin; Gregg B Fields
Journal:  J Biol Chem       Date:  2009-07-01       Impact factor: 5.157

10.  Molecular dissection of the structural machinery underlying the tissue-invasive activity of membrane type-1 matrix metalloproteinase.

Authors:  Xiao-Yan Li; Ichiro Ota; Ikuo Yana; Farideh Sabeh; Stephen J Weiss
Journal:  Mol Biol Cell       Date:  2008-05-21       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.